SIRT6 and breast cancer: Here, we identified TBX3 as a target downregulated by SIRT6 in both Delta16HER2- and HER2-positive breast cancer models, and we found that concomitant high SIRT6 and low TBX3 expression predicts poor prognosis in HER2-positive breast cancer patients.